Neurogene Inc.
NGNE
$29.82
-$1.45-4.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -30.93M | -24.74M | -20.95M | -22.02M | -22.65M |
| Total Depreciation and Amortization | 854.00K | 787.00K | 776.00K | 767.00K | 762.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.79M | 3.17M | 1.93M | 2.19M | 2.53M |
| Change in Net Operating Assets | 1.17M | 3.35M | -1.27M | -401.00K | -1.41M |
| Cash from Operations | -26.12M | -17.43M | -19.51M | -19.46M | -20.77M |
| Capital Expenditure | -281.00K | -128.00K | -127.00K | -148.00K | -780.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 46.52M | 29.74M | 22.12M | 7.60M | -44.27M |
| Cash from Investing | 46.24M | 29.61M | 21.99M | 7.45M | -45.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.00K | -19.00K | -13.00K | -14.00K | -15.00K |
| Issuance of Common Stock | 201.00K | 20.75M | 9.89M | 68.00K | 19.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -75.00K | -166.00K | -- | -- |
| Cash from Financing | 195.00K | 20.66M | 9.71M | 54.00K | 4.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 20.32M | 32.84M | 12.19M | -11.96M | -65.82M |